Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology...
Clinical Trial
Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Study site initiations in the United States for a randomized Phase 2/3 study of CTX-009 with paclitaxel in patients with Biliary...
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
Hamilton, Bermuda, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that...
Albireo to Participate in Jefferies London Healthcare Conference
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid...
Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today...
Revolo Biotherapeutics Announces That the Last Patient in its Phase 2a Trial of ‘1104 in Eosinophilic Esophagitis has Completed the Study
Topline data anticipated in early 2023NEW ORLEANS and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the...
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
Paper published in the November 2022 issue of Podiatry Management(Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM,...
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc....
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
HAMILTON, BERMUDA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- • Publication in International Archives of Allergy and Immunology shows rapid onset...
ExCellThera announces 100th patient treated with UM171-expanded cell therapy
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation,...
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase...
Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala’
Charity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE)...
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting
Table: Antiviral Effect of MAU868 vs. Placebo at Week 36 Table: Antiviral Effect of MAU868 vs. Placebo at Week 36New...
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients...
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis...
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase...
AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit
SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing...
Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker...
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a...
ORYZON to Give Updates on Corporate Progress in November
Kabuki Syndrome Foundation Annual Conference11th Drug Discovery Strategic SummitInv€$tival Showcase LSX Leaders 2022Jefferies London Healthcare Conference 2022MADRID, Spain and BOSTON,...